Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease
about
Targeted approaches to induce immune tolerance for Pompe disease therapyDurable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responsesImmune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent.Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in miceEnzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.Proteasome Inhibitor Bortezomib Enhances the Activity of Multiple Mutant Forms of Lysosomal α-Glucosidase in Pompe DiseaseBAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe diseaseImmune Tolerance Strategies in Siblings with Infantile Pompe Disease-Advantages for a Preemptive Approach to High-Sustained Antibody Titers.CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapyEngineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase.Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.Therapeutic advances in the management of Pompe disease and other metabolic myopathiesLong-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.Successful Desensitisation in a Patient with CRIM-Positive Infantile-Onset Pompe Disease.Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I.Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease.Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II.Letter to the Editors: Concerning "CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy" by Al Khallaf et al.Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study.Immune tolerance induced using plasma exchange and rituximab in an infantile Pompe disease patient.Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model.Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy.
P2860
Q26767363-B3223028-AB75-4098-8919-584821DA188DQ28595509-3200E4AD-791E-4C44-89D8-6DDB50C95EBAQ33711395-3AAE1EBE-DD96-45ED-9469-B49085F2EDA0Q34794660-02C0F9E5-38F5-4D1B-9A35-D42C2DFDC318Q35070412-9F05133C-9381-4A0E-9B5D-2FFC534C8F10Q35123163-EFA25DEE-F716-4943-9F0E-4F71F951B565Q35183088-81CBBA9B-C189-4582-95E5-B48F2D07FC09Q35732635-9DA27DAB-B525-41AA-A79A-5D214639712DQ35836295-4C3FAE28-E35D-4B9F-87DA-F1CE50B2D69AQ36030998-C7D1B669-86C5-4F30-B984-908CC279BB6EQ36284750-EE0A7E64-5A88-40C3-8908-C33E00E72205Q36953239-2F20CAF8-BA93-4EB9-B99E-528B5261DE1BQ37127561-7593D536-2288-4052-8658-72C37BD64F9BQ37394520-E818B58A-F215-483C-8E8A-25E87B7C7723Q37500689-8B65FB49-103B-4242-A653-CCB723E4E772Q37587722-AD76D46F-C113-4B76-9C2F-6C246B6B1EBEQ38621461-B44EAE5E-1B0E-4434-808F-1B3451B6A971Q38650286-EAA58D56-94C7-4486-AC5F-156F55211FFEQ38652950-9B48AB27-E01A-427A-8BDF-614A268CA61AQ38662053-2E416719-54C6-4E43-BA17-90BA04218D91Q39094272-F6ACCF05-F6F5-410C-9F9F-DD4EC96D6539Q43180517-321560DD-A05D-4083-A6F7-E9B8EDB9AB89Q43418166-4A8709D4-5367-4082-8D0F-56204D5B9BE3Q44603128-7A3ECA8D-6880-42F8-A930-BB6F72F9CC7AQ46207877-F648E791-7B21-40BA-8A49-F2AAB9F6CEDDQ48179948-AD0F7436-915B-43B6-A803-22F08E754B0B
P2860
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 October 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bortezomib in the rapid reduct ...... ons learned from Pompe disease
@en
Bortezomib in the rapid reduct ...... ns learned from Pompe disease.
@nl
type
label
Bortezomib in the rapid reduct ...... ons learned from Pompe disease
@en
Bortezomib in the rapid reduct ...... ns learned from Pompe disease.
@nl
prefLabel
Bortezomib in the rapid reduct ...... ons learned from Pompe disease
@en
Bortezomib in the rapid reduct ...... ns learned from Pompe disease.
@nl
P2093
P2860
P356
P1433
P1476
Bortezomib in the rapid reduct ...... ons learned from Pompe disease
@en
P2093
Amy S Rosenberg
Carrie Bailey
David Viskochil
Jesse A Tannenbaum
Jonathan D Feldman
Joyce A Kobori
Judeth K McGann
Priya S Kishnani
Renuka Gera
Robert L Conway
P2860
P2888
P304
P356
10.1038/GIM.2012.110
P407
P577
2012-10-11T00:00:00Z